Swipe om te navigeren naar een ander artikel
Understanding treatment satisfaction (TS) for diabetes is increasingly important as treatment options increase. This study examines treatment satisfaction with NovoMix® 30 in an observational study in patients with type 2 diabetes.
The DiabMedSat assesses Overall, Treatment Burden, Symptom and Efficacy Treatment Satisfaction. The impact of type of pretreatment variables on TS was examined by ANOVA at baseline and week 26. Satisfaction at week 26 was examined by t-test and effect size. Linear regression models examined impact of prior treatment factors (age, gender, duration of diabetes, type of prior treatment and diabetes-related comorbidities) and current treatment factors (weight gain, hypoglycemic events, reaching therapeutic goal) on TS.
The data set comprised 17,488 persons. Prior treatment with insulin had a more positive impact on baseline satisfaction. At week 26, there were no differences between type of prior treatment groups in Overall, Symptoms and Burden TS. Current treatment with NovoMix 30 significantly improved TS. Regression analyses examining the combined effect of pretreatment factors and current treatment factors found that all factors except for age-impacted TS although the domains impacted varied.
Patients treated with NovoMix 30 reported improved treatment satisfaction, and the improvement is considered clinically meaningful to patients.
Anderson, R. T., Marrero, D., Skovlund, S. E., Cramer, J., & Schwartz, S. (2003). Self-reported compliance with insulin injection therapy in subjects with type 1 and 2 diabetes [abstract]. Diabetologia, 46(Suppl 2), A275.
Centers for Disease Control and Prevention (CDC). (2008). National Center for Health Statistics, Division of Health Interview Statistics, data from the National Health Interview Survey. Age- adjusted percentage of adults with diabetes using diabetes medication, by type of medication, United States, 1997– 2008. Data computed by personnel in the Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion. http://www.cdc.gov/diabetes/statistics/meduse/fig2.htm. Accessed March 2, 2010.
Weijman, I., Ros, W. J., Rutten, G. E., Schaufeli, W. B., Schabracq, M. J., & Winnubst, J. A. (2005). Frequency and perceived burden of diabetes self-management activities in employees with insulin-treated diabetes: relationships with health outcomes. Diabetes Research and Clinical Practice, 68(1), 56–64. CrossRefPubMed
Franciosi, M., Maione, A., Pomili, B., Amoretti, R., Busetto, E., Capani, F., et al. (2010). Correlates of quality of life in adults with type 1 diabetes treated with continuous subcutaneous insulin injection. Nutrition, Metabolism and Cardiovascular Disease, 20(1), 7–14. CrossRef
Hollander, P. A., Blonde, L., Rowe, R., Mehta, A. E., Milburn, J. L., Hershon, K. S., et al. (2004). Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care, 27(10), 2356–2362. CrossRefPubMed
Quattrin, T., Bélanger, A., Bohannon, N. J., & Schwartz, S. L. (2004). Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care, 27(11), 2622–2627. CrossRefPubMed
Raskin, P., Bode, P. W., Marks, J. B., Hirsch, I. B., Weinstein, R. L., McGill, J. B., et al. (2003). Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel-group, 24 week study. Diabetes Care, 26(9), 2598–2603. CrossRefPubMed
Weintrob, N., Benzaquen, H., Galatzer, A., Shalitin, S., Lazar, L., Fayman, G., et al. (2003). Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: A randomized open crossover trial. Pediatrics, 112(3 Pt 1), 559–564. CrossRefPubMed
Bott, U., Ebrahim, S., Hirchberger, S., & Skovlund, S. E. (2003). Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetes Medicine, 209(8), 626–634. CrossRef
Valensi, P., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., et al. (2009). Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: Safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. International Journal of Clinical Practice, 63(3), 522–531. CrossRefPubMed
Nicolucci, A., Cucinotta, D., Squatrito, S., Lapolla, A., Musacchio, N., Leotta, S., et al. (2009). Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Disease, 19(1), 45–53. CrossRef
Alvarez Guisasola, F., Tofé Povedano, S., Krishnarajah, G., Lyu, R., Mavros, P., & Yin, D. (2008). Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes. Obesity and Metabolism, 10(Suppl 1), 25–32. CrossRef
Wild, D., Grove, A., Martin, M., Eremenco, S., McElroy, S., Verjee-Lorenz, A., et al. (2005). Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Value in Health, 8(2), 94–104. CrossRefPubMed
Ring, L., Hofer, S., Heuston, F., Harris, D., & O’Boyle, C. A. (2005). Response shift masks the treatment impact on patient reported outcomes (PROs): The example of individual quality of life in edentulous patients. Health and Quality of Life Outcomes, 7(3), 55. CrossRef
Valensi, P., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., et al. (2008). IMPROVE Study Group Expert Panel: The IMPROVE TM study—a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. International Journal of Clinical Practice, 62(11), 1809–1819. CrossRefPubMed
- Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors
Joseph A. Shaban
Don M. Bushnell
Torsten L. Christensen
- Springer Netherlands